Forus Raises US$160m for AI-Powered Medicine Platform

Key Takeaways

• Forus secured over $160 million from top venture firms.
• Platform automates insurance, assistance, and pharmacy routing for prescriptions.
• Adoption grew tenfold yearly, now in 80% of US zip codes.
• Five of the top ten global biopharma firms are platform partners.
• Free for doctors and patients, generating real‑time treatment data.

Pulse Analysis

The $160 million Series B round that Forus closed this month underscores the accelerating appetite of venture capital for AI‑driven health‑care infrastructure. Backed by Thrive Capital, General Catalyst, Accel and other marquee firms, the financing positions Forus alongside other high‑growth digital health players that are tackling the last‑mile gap between FDA approval and real‑world treatment. Investors are betting that a unified, data‑rich platform can not only streamline prescription fulfillment but also unlock new revenue streams for biopharma by exposing friction points in the care pathway. In a market where drug development costs average $2.6 billion, any efficiency gain is highly prized.

Forus’s technology embeds directly into physician electronic health records, automatically triggering insurance authorisation, financial‑assistance eligibility checks and pharmacy routing once a clinician selects a therapy. By eliminating manual paperwork, the system reduces the average time from prescription to first dose, a critical factor for patients with aggressive or rare diseases. The company reports a ten‑fold year‑over‑year increase in practice adoption, now covering roughly 80 percent of U.S. residential zip codes and serving thousands of health systems nationwide. Because the service is free for both doctors and patients, adoption is driven largely by word‑of‑mouth referrals rather than pricing incentives.

The data generated by Forus’s end‑to‑end workflow offers biopharma unprecedented visibility into where prescriptions stall, which patient sub‑populations drop out, and how drugs perform across diverse demographics. Five of the world’s top ten pharmaceutical companies have already integrated the platform, using its insights to refine clinical trial design and accelerate market launch strategies. As payers and regulators increasingly demand real‑world evidence, Forus could become a critical conduit for evidence‑based pricing and value‑based contracts. Competitors that lack such granular, real‑time data risk falling behind in a sector where speed to market and patient access are decisive competitive advantages.